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Global arginine bioavailability ratio
A B S T R A C T
Background: Major depressive disorder (MDD) is characterized by increased oxidative and nitrosative stress. We
compared nitric oxide metabolism, i.e., the global arginine bioavailability ratio (GABR) and related serum amino
acids, between MDD patients and non-depressed controls, and between remitted and non-remitted MDD pa-
tients.
Methods: Ninety-nine MDD patients and 253 non-depressed controls, aged 20–71 years, provided background
data via questionnaires. Fasting serum samples were analyzed using ultra-performance liquid chromatography
coupled to mass spectrometry to determine the serum levels of ornithine, arginine, citrulline, and symmetric and
asymmetric dimethylarginine. GABR was calculated as arginine divided by the sum of ornithine plus citrulline.
We compared the above measures between: 1) MDD patients and controls, 2) remitted (n=33) and non-remitted
(n = 45) MDD patients, and 3) baseline and follow-up within the remitted and non-remitted groups.
Results: Lower arginine levels (OR 0.98, 95% CI 0.97–0.99) and lower GABR (OR 0.13, 95% CI 0.03–0.50) were
associated with the MDD vs. the non-depressed group after adjustments for potential confounders. The remitted
group showed a decrease in GABR, arginine, and symmetric dimethylarginine, and an increase in ornithine after
the follow-up compared with within-group baseline values. The non-remitted group displayed an increase in
arginine and ornithine levels and a decrease in GABR. No significant differences were recorded between the
remitted and non-remitted groups.
Limitations: The MDD group was not medication-free.
Conclusions: Arginine bioavailability may be decreased in MDD. This could impair the production of nitric oxide,
and thus add to oxidative stress in the central nervous system.
1. Introduction
Major depression is the leading cause of disability and the global
burden of disease, and is the most common psychiatric disorder in
developed countries (WHO, 2014). However, the etiopathogenesis of
major depressive disorder (MDD) remains poorly understood. Earlier
studies have suggested aberrant nitric oxide (NO)-related pathways in
MDD. In one earlier study, the bioavailability of arginine, a precursor of
NO, was found to be decreased in inpatients with MDD (Baranyi et al.,
2015). Furthermore, decreased activity of the endothelial isoform of
nitric oxide synthase (eNOS) in platelets has been observed in MDD
(Chrapko et al., 2006). However, first-episode MDD patients have been
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shown to have increased levels of plasma nitrate, indicating increased
production of NO (Suzuki et al., 2001).
Nitric oxide (NO) is gaseous signaling molecule, which is formed
from the semi-essential amino acid arginine by three isoforms of nitric
oxide synthases (NOS) (Magariños and McEwen, 1995). These isoforms
are called inducible NOS (iNOS), neuronal NOS (nNOS), and en-
dothelial NOS (eNOS). NO modulates vasodilation and neuronal func-
tions, and inhibits the aggregation of platelets, adhesion of monocytes
and leucocytes, proliferation of smooth muscle cells, oxidation of low
density lipoprotein cholesterol (LDL), and vascular inflammation by
suppressing chemokines and adhesion molecules (Böger et al., 1998;
Cooke et al., 1991; Förstermann and Sessa, 2012; Tsao et al., 1996; Wolf
et al., 1997). Inducible NOS (iNOS) is mainly expressed by macro-
phages in response to inflammatory signals. However, virtually any cell
is capable of expressing iNOS (Förstermann and Sessa, 2012). In addi-
tion, NO decreases NMDA receptor activity (Lei et al., 1992; Manzoni
and Bockaert, 1993).
As the half-life of NO is short and NO is mostly synthesized on de-
mand at the site of need, there are no methods to reliably measure the
levels of NO. Therefore, the only possibility is to measure the bioa-
vailability of its precursor, which is also the limiting factor for the
synthesis of NO. Previously, the capacity to synthetize NO has been
estimated using the l-arginine/ornithine ratio, which reflects the ac-
tivity of arginase, an enzyme that competes with NOS for arginine.
However, the global arginine bioavailability ratio (GABR) is novel and
improved approach used to measure the capacity of a system to produce
NO, and has also been used as biomarker for endothelial dysfunction
and cardiovascular risk factors (Sourij et al., 2011). GABR is calculated
as the serum levels of arginine divided by the sum of ornithine plus
citrulline. The ratio gives a more precise estimation of the bioavail-
ability of arginine and thus the ability to produce NO (Morris et al.,
2005; Romero et al., 2008a, 2008b; Sourij et al., 2011).
Asymmetric dimethylarginine (ADMA) is an endogenous competi-
tive inhibitor of NOS (Vallance et al., 1992). Symmetric dimethylargi-
nine (SDMA) has no NOS-inhibiting qualities, but has been thought to
compete with the transportation of arginine through cell membranes
(Leiper et al., 1999).
One recent study reported increased levels of ADMA and decreased
levels of SDMA in patients with MDD (Baranyi et al., 2015).
In the present study, we analyzed the serum levels of arginine, ci-
trulline, and ornithine, and calculated GABR for a longitudinal sample
of MDD patients and for a non-depressed control group. Additionally,
we analyzed the levels of asymmetric and symmetric dimethylarginine
to assess the possible NOS-inhibiting role of these metabolites. These
metabolites and GABR were compared 1) between the MDD and non-
depressed groups and 2) within the MDD group between those who
recovered and did not recover during the follow-up of eight months.
Furthermore, we examined 3) changes in the metabolite levels during
the follow-up period within the groups of a) remitted MDD patients and
b) non-remitted MDD patients.
2. Methods
2.1. Study samples
The present study utilized two sample sets: 1) a naturalistic follow-
up study sample of patients with MDD and 2) a general population-
based sample of non-depressed individuals (Ali-Sisto et al., 2016). The
age distribution of the participants was 20–71 years. Both studies were
approved by the Ethics Committee of Kuopio University Hospital. All
participants provided written informed consent before entering the
study. Both study samples geographically represent the same popula-
tion.
The patient sample initially consisted of 100 outpatients with MDD,
and was recruited from the Department of Psychiatry at Kuopio
University Hospital. Due to a technical error during blood sample
handling, one sample was unusable, and thus the final sample set
consisted of 99 MDD patients. Due to the insignificant amount of
missing data, no attrition analyses were performed. At baseline, the
diagnosis of MDD was confirmed by using the Structured Clinical
Interview for DSM-IV (SCID) (DSM-IV American Psychiatric
Association, 1994). At the follow-up, the same criteria were used to
confirm clinical depression or the remission status. Of the initial 99
patients, 78 participated in the follow-up study (mean follow-up time 8
months; range 5–13 months). We observed no differences in age (p =
0.152), sex (p = 0.663), marital status (p = 0.575), alcohol use (p =
0.324), smoking (p = 0.964), regular exercise (p = 0.964), or BDI
scores (p = 0.493) between the depressed patients who participated in
the follow-up and those who did not. All participants gave venous blood
samples at baseline and on follow-up. The exclusion criteria for the
study were a history of epilepsy, bipolar disorder, psychotic disorders,
mental symptomology due to substance abuse, and current somatic
conditions preventing participation in the study.
At baseline, 84 (84.8%) of the patients used antidepressant medi-
cation and 48 (48.5%) used antipsychotic medication. Antidepressant
use was distributed as follows: 1) selective serotonin reuptake inhibitors
(SSRI), n = 42 (42.4%); 2) venlafaxine, n = 21 (21.2%); 3) mirtaza-
pine, n = 13 (13.1%); 4) duloxetine, n = 12 (12.1%); 5) moclobemide,
n = 8 (8.9%); 6) bupropion, n = 6 (6.1%), and 7) trazodone, n = 1
(1.0%).
The non-depressed control sample was a population-based long-
itudinal cohort of 480 individuals living in the municipality of
Lapinlahti, Finland. The sample included in this study was collected as
part of the 5-year follow-up of the Lapinlahti Study in 2010. Altogether,
257 non-depressed controls were derived from the population-based
Lapinlahti study sample. The exclusion criteria were an elevated level
of depressive symptoms, i.e., Beck Depression Inventory (BDI) scores
≥10 (Beck et al., 1961) at baseline or the 5-year follow-up of the La-
pinlahti Study, or the reported use of antidepressants. Participants
underwent a complete health examination and completed a background
questionnaire (Savolainen et al., 2014).
2.2. Background data
The following variables were extracted from questionnaires com-
pleted by the participants in both study samples: the frequency of
weekly physical exercise (≥1 times vs.< 1 time), regular smoking (yes
vs. no), weekly alcohol use (0–5 portions vs. ≥6 portions; 1 portion
corresponds to 1 bottle of beer, 1 glass of wine, or 4 cl of spirits),
marital status (married or living with a partner vs. living alone), edu-
cational level (university, polytechnic, or college education vs. lower
than university, polytechnic, or college education), and a physician-
determined diagnosis of hypertension (yes vs. no). Depressive symp-
toms were assessed with the 21-item BDI (range 0–63; Beck et al.,
1961). The use of prescription and over-the-counter medications was
also recorded with a questionnaire, and double-checked from the pre-
scription documents the patients provided at the study visit.
2.3. Laboratory analyses
Before venipuncture, the participants in both study populations
were instructed to fast for 12 h. All samples were stored at −70 °C until
analyzed. The blood samples were used to quantify the concentrations
of a batch of metabolites related to different aspects of the patient study
and the population-based Lapinlahti Study, from which the non-de-
pressed control sample was derived. Based on previous literature in-
dicating a role of NO in MDD, this study focused on the precursor of
NO, arginine, two closely related amino acids (i.e., ornithine and ci-
trulline), and two metabolites know to regulate NOS enzymes (sym-
metric and asymmetric dimethylarginine).
Metabolites were extracted from the serum samples using acetoni-
trile (1:4, sample:solvent) and analyzed using a WATERS XEVO-TQ-S
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triple quadrupole mass spectrometer coupled to an ACQUITY UPLC-
MS/MS system (Waters Corporation, Milford, MA, USA). A detailed
protocol and instrument conditions have been published elsewhere
(Roman-Garcia et al., 2014). GABR was calculated as arginine divided
by the sum of ornithine plus citrulline.
Serum high-density lipoprotein cholesterol (HDL-C; mmol/l) and
glycated hemoglobin (HbA1c; %) measurements were carried out ac-
cording to the routine protocol in the accredited medical laboratory of
Kuopio University Hospital. The analytical protocols have been de-
scribed in detail elsewhere (Chang et al., 1998; Siekmann et al., 1976).
2.4. Statistical methods
To analyze the differences between groups, we used the chi-squared
test and Fisher's exact test for categorical variables, and the Mann-
Whitney U-test for continuous variables due to a non-normal distribu-
tion of the variables. The normality of the distribution for the con-
tinuous variables was examined using the Kolmogorov-Smirnov test.
The changes in metabolite levels within the groups during the follow-up
period were analyzed using the Wilcoxon signed-rank test. Correlations
between the measured metabolites or GABR and variables related to the
risk of cardiovascular morbidities were analyzed using Spearman's
correlation coefficient or the Mann-Whitney U-test. Effect sizes for the
analyzed group differences were calculated using an online calculator
at http://www.socscistatistics.com/effectsize/Default3.aspx. Using the
power of 0.80 and an alpha level of 0.05, the study sample had statis-
tical power to detect effects (Cohen's d) larger than 0.32 in the setting of
MDD vs. non-depressed controls and 0.62 in the follow-up analyses
(i.e., remitted vs. non-remitted MDD patients).
Logistic regression analysis (method: enter) was carried out. For
baseline analyses, we constructed three models: the basic model (Model
1) was adjusted for age and gender. In the lifestyle model (Model 2),
three factors (regular smoking, physical exercise, and alcohol use) were
added to Model 1 to investigate the potential confounding effects of
lifestyles factors. In the socioeconomic model (Model 3), education and
marital status were added to Model 1. In the metabolic model (Model
4), serum levels of glycated hemoglobin (HbA1C) and fasting serum
levels of high density lipoprotein cholesterol (HDL-C) were added to
Model 2 to evaluate the potential confounding effect of metabolic
status. Model 4 was constructed based on Model 2 rather than Model 3,
because Model 2 showed a greater goodness-of-fit (−2 log likelihood)
compared to Model 3. The potential confounders were chosen based on
a known influence of the examined variables (HbA1C and HDL-C, Peng
et al., 2015; Zieliński and Kusy, 2015), or an observed difference be-
tween the investigated groups (regular smoking; physical exercise; al-
cohol use; see Table 1).
In the follow-up setting and in analyses comparing the remitted or
non-remitted MDD groups and the non-depressed control group, a
smaller number of participants (n = 78) was available for analysis.
Thus, fewer variables were utilized as covariates in the multivariate
analysis in order to remain within the recommended 10% limit and
avoid overfitting of the models (Babyak, 2004). Two models were
tested. The basic follow-up model (Model 1) was identical to Model 1
used in the baseline setting, and was adjusted for age and gender.
Follow-up Model 2 was further adjusted for physical exercise, as the
level of physical exercise significantly differed between the remitted
and non-remitted groups.
The possible confounding role of medication was assessed in two
steps. First, the Mann-Whitney U-test was used to detect possible group
differences in metabolite levels between MDD patients using and not
using 1) any antidepressant, 2) SSRIs, 3) duloxetine, 4) venlafaxine, 5)
mirtazapine, or 6) any antipsychotic. We did not examine the specific
effects of bupropion or trazodone due to the small group sizes (bu-
propion, n = 6; trazodone, n = 1). Secondly, the possible confounding
role of medications was further assessed by repeating the baseline
multivariate Model 2 after the exclusion of individuals on any
medication with significant metabolite differences between medication
users vs. non-users. Model 4 was not applied to avoid over-adjusting the
sample smaller following the exclusions (Babyak, 2004). All analyses
were performed with SPSS 21.0 for Windows statistical software (SPSS
Inc., Chicago, IL). Two-tailed p-values below 0.05 were considered to
indicate statistical significance.
3. Results
3.1. MDD patients vs. non-depressed controls at baseline
The participants with MDD were younger than the non-depressed
controls. Furthermore, they were more likely to smoke and less likely to
exercise regularly (Table 1). GABR and the serum levels of arginine and
symmetric dimethylarginine were lower in participants with MDD
compared to non-depressed controls (Table 2). Effect sizes (Cohen's d)
for group differences in the measured metabolites were 0.48 for GABR
(p< 0.001), 0.68 for arginine (p< 0.001), 0.16 for citrulline (p =
0.259), 0.08 for ornithine (p = 0.460), 0.32 for symmetric dimethy-
larginine (p = 0.045), and 0.18 for asymmetric dimethylarginine (p =
0.460).
After fully adjusted logistic regression analysis (Model 4, Table 3),
GABR and the serum levels of arginine remained significantly different
between the participants with MDD and the non-depressed controls.
Age and GABR correlated in the MDD group (ρ=−0.281, p=0.005),
but not in control group (ρ=−0.058, p=0.355).
3.2. Metabolites associated with MDD remission status at the follow-up
At the time of the follow-up, 45 (57.7%) patients still fulfilled the
criteria for MDD, whereas 33 (42.3%) had recovered. Non-remitted
participants had higher baseline BDI scores and were less likely to ex-
ercise regularly than remitters (Table 1). Effect sizes (Cohen's d) for
group differences in the measured metabolites were 0.08 for GABR (p
= 0.836), 0.32 for arginine (p = 0.125), 0.24 for citrulline (p =
0.259), 0.06 for ornithine (p = 0.421), 0.17 for symmetric dimethy-
larginine (p = 0.349), and 0.22 for asymmetric dimethylarginine (p =
0.404). At the follow-up, remitted and non-remitted participants dis-
played no significant differences with regard to the investigated me-
tabolites or GABR (Table 2). After fully adjusted logistic regression
analysis (Model 4), no differences between groups emerged.
3.3. Within-group changes in metabolite levels during the follow-up period
During the follow-up period, MDD patients in the remitted group
displayed increased GABR and levels of arginine and symmetric di-
methylarginine, whereas the levels of ornithine decreased. In the non-
remitted group, GABR and levels of arginine increased and levels of
ornithine decreased over the follow-up period (Table 2, Table 4).
3.4. Correlations between depressive symptoms and measured metabolites
Within the MDD group, neither BDI scores nor the change in BDI
scores correlated with any of the measured metabolites or GABR.
Metabolite changes from baseline to the follow-up did not correlate
with changes in BDI scores (Supplementary Table 1).
3.5. Measured metabolites and variables affecting cardiovascular risk
In the MDD group, those who had a diagnosis of high blood pressure
(n = 32) had lower GABR (p = 0.003, Z = −2.940) and higher levels
of ornithine (p = 0.009, Z = −1.855) than those without a diagnosis
(n = 67). However, HDL showed no correlation with the measured
metabolites or GABR (p = 0.307, ρ = −0.104).
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Table 1
Characteristics of the study groups at baseline. Values are medians (interquartile ranges) unless otherwise stated.






Test statistics Test value (p-value)
MDD vs controls Remitted vs
non-remitted
Age, mean (SD) 39.41 (11.94) 37.76 (12.82) 43.42 (10.13) 55.28 (10.08) t = 12.60 (< 0.001)a t = 2.17 (0.080)a
Female, n (%) 56 (56.6) 17 (51.5) 28 (62.2) 129 (51.0) χ2 = 0.89 (0.346)b χ2 = 0.89 (0.344)b
Married or living with a partner, n (%) 84 (84.4) 18 (54.5) 20 (44.4) 213 (84.2) χ2 = 0.02 (0.878)b χ2 = 0.78 (0.378)b
University, polytechnic, or college
education, n (%)
36 (36.4) 6 (18.8) 16 (35.6) 88 (34.8) χ2 = 0.08 (0.780)b χ2 = 2.59 (0.108)b
Regular smoking, n (%) 29 (29.3) 14 (42.4) 12 (26.7) 26 (10.3) χ2 = 19.52
(< 0.001)b
χ2 = 2.13 (0.145)b
Significant alcohol usage, n (%) 22 (22.2) 12 (36.4) 17 (37.8) 36 (14.2) χ2 = 3.10 (0.069)b χ2 = 0.016 (0.898)b
Regular exercise, n (%) 43 (42.4) 28 (84.8) 21 (46.7) 243 (96.0) χ2 = 132.77
(< 0.001)b
χ2 = 11.88 (0.001)b
HbA1C (%) 4.9 (4.3–5.5) – – 5.6 (5.4–5.9) Z = −8.02
(< 0.001)c
–
HDL-C (mmol/l) 1.0 (0.7–1.5) 1.56 (1.19–1.99) 1.39 (1.15–1.83) 1.4 (1.1–1.7) Z = −5.20
(< 0.001)c
Z = −1.03 (0.302)c
Diabetes, n (%) 5 (5.1) 1 (3.0) 3 (6.7) 21 (8.2) χ2 = 1.10 (0.295)b χ2 = 0.52 (0.472)b
Arterial hypertension, n (%) 32 (32.3) 6 (18.2) 19 (42.2) 78 (30.8) χ2 = 0.07 (0.786)b χ2 = 5.05 (0.025)b
Coronary artery disease, n (%) 3 (3.0) 1 (3.0) 2 (4.4) 7 (2.8) χ2 = 0.18 (0.894)b χ2 = 0.10 (0.748)b
Asthma, n (%) 12 (12.1) 2 (6.1) 7 (15.6) 22 (8.6) χ2 = 0.95 (0.328)b χ2 = 1.68 (0.195)b
BDI scores 29 (19.0–36.0) 16 (7–23) 32 (20–39) 2.0 (0.0–4.0) Z = −14.12
(< 0.001)c
Z = −5.05 (< 0.001)c






Characteristics of the study groups. Values are medians (interquartile ranges).









GABR Baseline 0.86 (0.63–1.08) 0.75 (0.61–1.07) 0.84 (0.62–1.10) 1.01 (0.79–1.28) Z = −4.18
(< 0.001)
Z = −0.21 (0.836)
Follow-up – 1.18 (0.89–1.42) 1.04 (0.86–1.35) – – Z = −0.75 (0.451)
Change – 0.42 (0.06–0.57) 0.23 (−0.02–0.52) – – Z = −1.03 (0.305)


















– – Z = −0.54 (0.588)
Citrulline Baseline 29.01 (22.01–33.69) 29.06 (19.84–33.38) 29.27 (24.00–36.49) 29.44 (23.31–36.61) Z=−1.13
(0.259)
Z=−0.93 (0.355)
Follow-up – 27.41 (22.37–33.46) 30.45 (24.24–40.41) – – Z=−1.78 (0.076)









Z = −0.80 (0.421)
Follow-up – 79.96
(51.07–101.13)





– – Z = −0.15 (0.883)
Symmetric
dimethylarginine
Baseline 1.25 (0.94–1.61) 1.23 (0.83–1.59) 1.26 (1.10–1.59) 1.42 (1.03–1.85) Z = −2.00
(0.045)
Z = −1.00 (0.349)
Follow-up – 1.37 (1.11–1.87) 1.39 (0.96–1.87) – – Z = −0.36 (0.720)
Change – 0.26 (−0.42–0.84) 0.05 (−0.52–0.69) – – Z = −0.87 (0.287)
Asymmetric
dimethylarginine
Baseline 0.76 (0.58–0.97) 0.76 (0.48–0.96) 0.79 (0.61–0.96) 0.79 (0.56–1.02) Z = −0.74
(0.460)
Z = −0.84 (0.404)
Follow-up – 0.73 (0.55–0.97) 0.79 (0.50–1.12) – – Z = −0.47 (0.638)
Change – 0.13 (−0.28–0.43) 0.02 (−0.39–0.49) – – Z = −0.33 (0.742)
cMann-Whitney U-test.
Abbreviations: MDD, major depressive disorder; GABR, global arginine bioavailability ratio.
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3.6. The effect of medication use in the MDD sample
In the MDD group, the use of duloxetine (n = 12) was associated
with higher levels of citrulline (p = 0.034), the use of bupropion (n =
6) was associated with higher levels of arginine (p = 0.011) and or-
nithine (p = 0.033), and the use of mirtazapine (n = 13) was asso-
ciated with lower GABR (p = 0.038). The use of an SSRI, venlafaxine,
any antidepressant medication (Table 5), or any antipsychotic medi-
cation did not associate with alterations in the metabolite levels. In
multivariate Model 2 with users of duloxetine, bupropion, or
mirtazapine excluded, the significant results were similar to the ana-
lyses in which users of these antidepressants were included (Table 3).
4. Discussion
4.1. Summary of the main findings
Firstly, we observed lower serum levels of arginine as well as a
lower GABR in the MDD group compared to the control group at
baseline. These findings persisted, regardless of adjustments for age,
gender, alcohol use, regular smoking, physical exercise, HbA1C, and
HDL-C. Secondly, at the follow-up, contrary to our hypotheses, no
significant differences in the changes in metabolite levels were ob-
served between remitted vs. non-remitted groups. Thirdly, within the
remitted group, GABR and the levels of arginine and symmetric di-
methylarginine increased over the follow-up period, whereas the levels
of ornithine decreased. Within the non-remitted group, GABR and the
levels of arginine increased, while the levels of ornithine decreased over
the follow-up period. The increase in GABR was higher in the remitted
group than in the non-remitted group.
4.2. Comparison with the existing literature
To the best of our knowledge, only two earlier studies have been
published on GABR in psychiatric disorders (Baranyi et al., 2015;
Bersani et al., 2016). Baranyi et al. (2015) investigated GABR, SDMA,
ADMA, and the arginine/ADMA ratio in 71 inpatients suffering from
MDD and 48 healthy controls. They found no difference in GABR be-
tween in-patients at the time of hospitalization and healthy controls.
Furthermore, they observed elevated levels of ADMA and lowered le-
vels of SDMA in MDD patients compared to controls. However, we
observed a decreased GABR in MDD patients compared to controls and
no differences in ADMA or SDMA in this study. Baranyi et al. recorded a
non-significant increase in GABR during the time of hospitalization. In
the present study, GABR significantly increased in both remitted and
non-remitted groups during an average follow-up time of eight months.
Compared to the present study, Baranyi et al. had a slightly smaller
group size and investigated inpatients instead of outpatients. In general,
inpatients tend to have either more severe or more acute symptoms
than outpatients. Possibly, this could affect the differences in GABR or
the measured metabolites between the study populations. However, our
outpatient sample displayed slightly higher BDI scores (mean 29)
compared to those of the inpatient sample of Baranyi et al. (mean 24).
Moreover, Baranyi and co-workers utilized symptom scales instead of
structured diagnostic methods. The present study was also able to assess
potential confounders with multivariate models. Bersani et al. (2016)
determined GABR in soldiers with and without posttraumatic stress
disorder (PTSD), finding lower GABR in the participants with PTSD
than the controls. Their results remained significant after adding di-
agnoses of MDD and antidepressant use as confounders to the multi-
variate model, suggesting an independent association between PTSD
and GABR. Thus, decreased GABR may be a non-specific marker for
several psychiatric disorders. In addition to psychiatric disorders, de-
creased GABR has been associated with increased cardiovascular mor-
bidity and mortality from cardiovascular diseases (Sourij et al., 2011;
Tang et al., 2009), which are both closely linked with depression
(Penninx, 2016). In our sample, the depressed population was sig-
nificantly younger compared to the non-depressed controls, and we also
detected a correlation between age and GABR, but adjusting for age in
the multivariate model did not affect our observations.
Baranyi et al. (2015) used solid phase extraction (SPE) and a deri-
vatization method for the extraction of metabolites. Furthermore, they
separated and detected the extracted metabolites by HPLC with a
fluorescence detector. We used a one-step protein precipitation method
for metabolite extraction. The extracted metabolites were detected
using liquid chromatography–mass spectrometry, which is more
Table 3
Odds ratios (OR) and 95% confidence intervals (CI) for the likelihood of belonging to the
major depressive disorder group vs. the non-depressed group for each one-unit increase in
the serum levels of each metabolite or the GABR.
OR 95% CI p value
GABR Model 1 0.43 0.30–0.60 < 0.001
Model 2 0.53 0.35–0.81 0.003
Model 3 0.43 0.30–0.61 < 0.001
Model 4 0.51 0.32–0.80 0.003
Model 2a 0.54 0.33–0.88 0.014
Arginine Model 1 0.52 0.37–0.74 < 0.001
Model 2 0.54 0.35–0.82 0.004
Model 3 0.52 0.37–0.73 < 0.001
Model 4 0.57 0.36–1.91 0.018
Model 2a 0.48 0.28–0.83 0.008
Citrulline Model 1 1.25 0.93–1.67 0.139
Model 2 1.25 0.88–1.78 0.217
Model 3 1.24 0.92–1.67 0.153
Model 4 1.37 0.91–2.06 0.128
Model 2a 1.10 0.72–1.68 0.669
Ornithine Model 1 1.39 1.05–1.84 0.023
Model 2 1.06 0.74–1.52 0.760
Model 3 1.38 1.04–1.83 0.028
Model 4 1.23 0.82–1.86 0.319
Model 2a 0.98 0.65–1.45 0.935
Symmetric dimethylarginine Model 1 0.88 0.63–1.24 0.472
Model 2 0.83 0.53–1.31 0.416
Model 3 0.88 0.63–1.24 0.474
Model 4 0.84 0.52–1.36 0.472
Model 2a 0.77 0.45–1.37 0.379
Asymmetric dimethylarginine Model 1 1.03 0.75–1.43 0.842
Model 2 1.04 0.67–1.58 0.849
Model 3 1.03 0.75–1.43 0.836
Model 4 1.06 0.67–1.68 0.800
Model 2a 1.03 0.63–1.70 0.900
Model 1: Adjusted for age and gender.
Model 2: Model 1 further adjusted for regular smoking, significant alcohol use, and
regular exercise.
Model 3: Model 1 further adjusted for university, polytechnic, or college education and
cohabitation.
Model 4: Model 2 further adjusted for B-HbAC1 and high-density lipoprotein cholesterol.
Abbreviations: OR, odds ratio; CI, confidence interval; GABR, global arginine bioavail-
ability ratio.
a Analyses with users of duloxetine, bupropion, and mirtazapine excluded.
Table 4
Longitudinal changes in metabolite levels from baseline to follow-up within the remitted
and non-remitted MDD groups.
Remitted (n = 33),
Z (p-value)*
Non-remitted
(n = 45), Z (p-value)*
GABR −3.53 (p< 0.001) −3.00 (p = 0.003)
Arginine −3.31 (p = 0.001) −2.87 (p = 0.004)
Citrulline −0.06 (p = 0.950) −1.23 (p = 0.221)
Ornithine −2.15 (p = 0.031) −2.27 (p = 0.023)
Symmetric dimethylarginine −2.99 (p = 0.046) −1.03 (p = 0.302)
Asymmetric dimethylarginine −0.81 (p = 0.416) −0.29 (p = 0.773)
Abbreviations: MDD, major depressive disorder; GABR, global arginine bioavailability
ratio.
* Wilcoxon signed-rank test.
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specific and sensitive compared to HPLC. We also used isotope-labelled
internal standards to avoid a matrix effect during analysis in order to
obtain optimized quantification. Finally, the metabolites were quanti-
fied from the area ratio (area of metabolites/area of internal standards
(IS)) using calibration curves.
4.3. Possible mechanisms
Decreased GABR may indicate that the ability to produce NO is
compromised or that the system has been producing NO in relatively
large amounts to deplete the arginine supply. Increased NO production
has been suggested to have a role in the etiopathogenesis of MDD.
Suzuki et al. (2001) recorded increased plasma nitrate levels in MDD
patients compared to patients with anxiety disorders, and found an
increased production of NO.
INOS is activated as a response to inflammatory cytokines (e.g.,
interleukin-1 [IL]−1, tumor necrosis factor [TNF]-alpha, and inter-
feron gamma), and produces relatively large amounts of NO (Green
et al., 1994; Knowles and Moncada, 1994). As MDD has been observed
to be characterized by increased levels of proinflammatory cytokines
(e.g. Valkanova et al., 2013), increased NO production induced by the
pro-inflammatory state remains a fitting hypothesis for decreased
GABR. MDD has been linked to a high state of oxidative and nitrosative
stress, both of which are tied to inflammatory responses (Maes et al.,
2011). Alternatively to or simultaneously with the possible increased
activation of iNOS, decreased GABR could result from increased activity
of the arginase enzyme. Arginase competes with NOS and converts
arginine to ornithine, and is upregulated in conditions such as diabetes
mellitus and inflammation (Morris et al., 2005; Maritza J. Romero
et al., 2008a, 2008b).
MDD has been reported to be characterized by increased cardio-
vascular morbidity (Penninx, 2016). This association between depres-
sive traits and cardiovascular events has been suggested to be explained
by low-grade inflammation (Tolmunen et al., 2015). An inflammation-
induced decrease in GABR might be one of the biological mechanisms
behind the comorbidity of MDD and cardiovascular diseases. Decreased
GABR has been reported to be a marker of increased cardiovascular
mortality in patients hospitalized for coronary angiography (Sourij
et al., 2011). In the present study, GABR was lower in MDD patients
who had a diagnosis of hypertension compared to those patients with
no diagnosis of hypertension.
If the ability to produce NO has been compromised due to decreased
GABR, the neuronal functions of NO might also be compromised. In the
central nervous system (CNS), nNOS produces NO and has generally
been associated with synaptic plasticity, memory, long-term potentia-
tion, and the regulation of blood pressure (Förstermann and Sessa,
2012). One of the known mechanisms of induction of NO production in
the CNS is the activation of nNOS by an increased influx of Ca ions due
to the activation of NMDA receptors (Bredt and Snyder, 1990;
Weissman et al., 2002). The NMDA receptor has been studied as a
pharmacological target for psychiatric treatments (Réus et al., 2016;
Zorumski et al., 2015).
We did not observe significant group differences between the
remitted and non-remitted MDD groups. Thus, it remains unclear how
GABR changes during remission, and how quickly such effects might
occur. The statistical power of the setting comparing remitted with non-
remitted MDD patients was lower than that of the setting comparing
MDD patients with non-depressed controls, and it is therefore possible
that a larger sample comparing remitted with non-remitted MDD pa-
tients could detect differences in GABR. Nevertheless, it is possible that
the differences observed between MDD patients and non-depressed
controls in this study do not normalize during remission. Similar studies
with larger group sizes and longer follow-up durations should be con-
ducted to gain a better understanding of GABR kinetics during the re-
mission phase of MDD.
4.4. Strengths and limitations
The strengths of the present study are the relatively large group size
and the possibility to investigate the potential confounding effects of
several possible biasing factors. Nevertheless, having a larger sample of
depressed individuals might have allowed a more exact evaluation of
potential differences in GABR between remitted and non-remitted MDD
patients. Having access to a medication-free MDD sample would have
allowed possible medication effects on NO metabolism to be excluded.
Nevertheless, our observations remained unaltered after the exclusion
of participants using medications that demonstrated associations with
alterations in the investigated metabolites. Furthermore, the possibility
to measure the activities of three isoforms of NOS and having access to
more variables linked to cardiovascular morbidities would have further
enhanced our analyses.
5. Conclusions
Major depressive disorder might be associated with the decreased
bioavailability of arginine, which could impair the synthesis of nitric
oxide.
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Table 5
Characteristics of the users and non-users of antidepressants at baseline. Values are medians (interquartile ranges).
Any antidepressant n = 84 No antidepressants n = 15 Test statisticsc p-valuea
GABR 0.86 (0.65–1.13) 0.87 (0.60–1.01) −0.77 0.441
Arginine 101.31 (85.72–116.36) 85.99 (73.58–111.05) −1.53 0.125
Ornithine 86,21 (68.65–117.31) 96.58 (79.37–105.03) −0.04 0.969
Citrulline 29.11 (22.06–34.22) 28.80 (18.49–31.77) −0.96 0.339
Symmetric dimethylarginine 0.79 (0.58–0.96) 0.60 (0.27–1.00) −1.83 0.208
Asymmetric dimethylarginine 1.26 (0.97–2.62) 1.11 (0.56–1.57) −1.26 0.068
Abbreviations: GABR, global arginine bioavailability ratio.
a Mann-Whitney U-test (Z).
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